Prueksaritanont T - Search Results

1

Mechanistic studies on metabolic interactions between gemfibrozil and statins.

Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, Baillie TA. Prueksaritanont T, et al. J Pharmacol Exp Ther. 2002 Jun;301(3):1042-51. doi: 10.1124/jpet.301.3.1042. J Pharmacol Exp Ther. 2002. PMID: 12023536

2

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.

Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, Baillie TA. Prueksaritanont T, et al. Drug Metab Dispos. 2002 May;30(5):505-12. doi: 10.1124/dmd.30.5.505. Drug Metab Dispos. 2002. PMID: 11950779

3

Effects of fibrates on metabolism of statins in human hepatocytes.

Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Prueksaritanont T, et al. Drug Metab Dispos. 2002 Nov;30(11):1280-7. doi: 10.1124/dmd.30.11.1280. Drug Metab Dispos. 2002. PMID: 12386136

4

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.

Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, Liu L, Lasseter KC, He W, Prueksaritanont T, Qiu Y, Hartford A, Vega JM, Paolini JF. Bergman AJ, et al. Among authors: prueksaritanont t. J Clin Pharmacol. 2004 Sep;44(9):1054-62. doi: 10.1177/0091270004268044. J Clin Pharmacol. 2004. PMID: 15317833 Clinical Trial.

5

Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil.

Prueksaritanont T, Qiu Y, Mu L, Michel K, Brunner J, Richards KM, Lin JH. Prueksaritanont T, et al. Pharm Res. 2005 Jul;22(7):1101-9. doi: 10.1007/s11095-005-6037-2. Epub 2005 Jul 22. Pharm Res. 2005. PMID: 16028010

6

Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.

Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, Reider PJ, Lin JH, Baillie TA. Prueksaritanont T, et al. Br J Clin Pharmacol. 1999 Mar;47(3):291-8. doi: 10.1046/j.1365-2125.1999.00903.x. Br J Clin Pharmacol. 1999. PMID: 10215754 Free PMC article.

7

Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects.

Prueksaritanont T, Vega JM, Zhao J, Gagliano K, Kuznetsova O, Musser B, Amin RD, Liu L, Roadcap BA, Dilzer S, Lasseter KC, Rogers JD. Prueksaritanont T, et al. J Clin Pharmacol. 2001 May;41(5):573-81. doi: 10.1177/00912700122010311. J Clin Pharmacol. 2001. PMID: 11361054 Clinical Trial.

8

The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

Prueksaritanont T, Ma B, Yu N. Prueksaritanont T, et al. Br J Clin Pharmacol. 2003 Jul;56(1):120-4. doi: 10.1046/j.1365-2125.2003.01833.x. Br J Clin Pharmacol. 2003. PMID: 12848784 Free PMC article.

9

Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin.

Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, Prueksaritanont T. Hochman JH, et al. Among authors: prueksaritanont t. Pharm Res. 2004 Sep;21(9):1686-91. doi: 10.1023/b:pham.0000041466.84653.8c. Pharm Res. 2004. PMID: 15497697

10

Bioactivation of 2,3-diaminopyridine-containing bradykinin B1 receptor antagonists: irreversible binding to liver microsomal proteins and formation of glutathione conjugates.

Tang C, Subramanian R, Kuo Y, Krymgold S, Lu P, Kuduk SD, Ng C, Feng DM, Elmore C, Soli E, Ho J, Bock MG, Baillie TA, Prueksaritanont T. Tang C, et al. Among authors: prueksaritanont t. Chem Res Toxicol. 2005 Jun;18(6):934-45. doi: 10.1021/tx0500427. Chem Res Toxicol. 2005. PMID: 15962928

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

142 results

Search Page